NEW YORK (GenomeWeb News) – Molecular diagnostics firm PrimeraDx today announced a deal with Eli Lilly to develop diagnostics in support of the drug firm's therapeutic development programs.

The multiyear deal calls for the two firms to collaborate on the development of multiplex assays on PrimeraDx's ICEPlex System, an automated, high-throughput real-time PCR and capillary electrophoresis instrument. Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.